Background and design of a 5-year ST Elevation Myocardial Infarction Cohort in Isfahan, Iran: SEMI-CI study

(2022) Background and design of a 5-year ST Elevation Myocardial Infarction Cohort in Isfahan, Iran: SEMI-CI study. ARYA ATHEROSCLEROSIS. ISSN 17353955 (ISSN)

Full text not available from this repository.

Abstract

BACKGROUND: Cardiovascular disease (CVD) is one of the most important causes of mortality and morbidity in Iran. Secondary prevention of acute myocardial infarction (AMI) is necessary. The main aim of this cohort is evaluating clinical, paraclinical, management, and 5-year major events of the participants in Isfahan, Iran. METHODS: All consecutive patients with AMI hospitalized in Chamran Hospital, Isfahan, during 1 year from march 2015 were recruited and followed for 5 years. ST-Elevation Myocardial Infarction Cohort Study (SEMI-CI) has been initiated as a longitudinal study to evaluate course of patients with AMI in Iran, adherence to evidence-based secondary prevention drug, and five-year events such as death, re-myocardial infarction (REMI), re-hospitalization, congestive heart failure (CHF), and referring to another procedure percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG), and resynchronization therapy. RESULTS: A total of 867 patients with ST-elevation myocardial infarction (STEMI) with mean age of 60.91 ± 12.76 years were recruited. 705 (81.3%) subjects were men with mean age of 59.63 ± 12.59 years. 470 (54.2%) patients had anterior AMI (ant-AMI) and the rest had other types of AMI. The ejection fraction (EF) mean was 37.80 ± 11.74 percent. A total of 30 (3.5%) cases of AMI had not received reperfusion. 445 (51.4%) had primary PCI and 392 (45.2%) had thrombolysis at first revascularization strategy. In-hospital death occurred in 72 participants (8.3%). Drug during hospital included: at discharge, 767 (88.5%) received aspirin, 787 (90.7%) statin, 697 (80.4%) beta-blocker, and 480 (55.4%) angiotensin-converting enzyme (ACE) inhibitor. CONCLUSION: According to the best of our knowledge, it is among few cohorts in Eastern Mediterranean Region (EMR) in patients with AMI. This paper showed methodology of this study in patients with STEMI and its follow-up protocol. We can use this result in policy-making for improving secondary prevention strategies. © 2022, Isfahan University of Medical Sciences(IUMS). All rights reserved.

Item Type: Article
Keywords: Cohort Study Death Myocardial Infarction Secondary Prevention acetylsalicylic acid angiotensin receptor antagonist atenolol atorvastatin beta adrenergic receptor blocking agent captopril carvedilol clopidogrel creatinine dipeptidyl carboxypeptidase inhibitor enalapril enoxaparin eplerenone ezetimibe fibric acid derivative furosemide hemoglobin heparin hydrochlorothiazide isoenzyme lisinopril losartan low density lipoprotein cholesterol mevinolin opiate prasugrel propranolol rosuvastatin simvastatin spironolactone statin (protein) ticlopidine triamcinolone acetonide triamterene valsartan warfarin adult aged angiography angioplasty Article blood clot lysis blood pressure cardiac resynchronization therapy clinical feature cohort analysis coronary artery bypass graft design electrocardiography female follow up glucose blood level heart ejection fraction heart left bundle branch block heart rate heart rhythm hemodynamics hospitalization human Iran longitudinal study major clinical study male percutaneous coronary intervention prescription psychologic assessment questionnaire reperfusion ST segment elevation myocardial infarction stent thrombosis very elderly
Journal or Publication Title: ARYA ATHEROSCLEROSIS
Journal Index: Scopus
Volume: 17
Number: 2
Identification Number: https://doi.org/10.22122/arya.v17i0.2375
ISSN: 17353955 (ISSN)
Depositing User: Zahra Otroj
URI: http://eprints.mui.ac.ir/id/eprint/16984

Actions (login required)

View Item View Item